Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Firefly Neuroscience, Inc. (AIFF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: AIFF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -90.59% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.09M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 1387713 | Beta - | 52 Weeks Range 1.86 - 17.20 | Updated Date 03/15/2025 |
52 Weeks Range 1.86 - 17.20 | Updated Date 03/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -12590% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 27185213 | Price to Sales(TTM) 423.28 |
Enterprise Value 27185213 | Price to Sales(TTM) 423.28 | ||
Enterprise Value to Revenue 56.75 | Enterprise Value to EBITDA - | Shares Outstanding 7341390 | Shares Floating 6011613 |
Shares Outstanding 7341390 | Shares Floating 6011613 | ||
Percent Insiders 44.82 | Percent Institutions 1.03 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Firefly Neuroscience, Inc.
Company Overview
History and Background
Firefly Neuroscience, Inc. is a company focused on advancing clinical decision-making through brain health insights. Founded in 2009 as NeuroWave Systems, it has evolved through various funding rounds and strategic shifts to its current focus on EEG-based diagnostics for cognitive and mental health.
Core Business Areas
- Brain Vital Signs Platform: Offers a software platform analyzing EEG data to provide objective, quantitative insights into brain function.
- Clinical Decision Support Tools: Develops tools to aid clinicians in diagnosing and treating cognitive and mental health disorders, based on EEG analysis.
Leadership and Structure
The leadership team includes a CEO, CFO, and other executives responsible for R&D, commercialization, and operations. The organizational structure is typical of a clinical-stage medical device company, with departments focused on research, product development, sales, and marketing.
Top Products and Market Share
Key Offerings
- Firefly Brain Vital Signs Platform: This platform analyzes EEG data using proprietary algorithms to provide objective measures of brain function. Market share data is not publicly available. Competitors include companies that offer EEG-based diagnostic tools such as BrainScope and companies developing biomarkers for cognitive and mental health disorders like Alto Neuroscience. Data on number of users or revenue is also not available.
Market Dynamics
Industry Overview
The industry is characterized by increasing demand for objective measures in diagnosing and treating cognitive and mental health disorders. There's a growing interest in EEG-based diagnostics and digital biomarkers.
Positioning
Firefly Neuroscience positions itself as a provider of objective, quantitative brain health insights that can improve clinical decision-making. Its competitive advantage lies in its proprietary EEG analysis algorithms and the potential for personalized treatment strategies.
Total Addressable Market (TAM)
The TAM for cognitive and mental health diagnostics is estimated to be in the billions of dollars. Firefly Neuroscience is positioned to capture a segment of this market by offering EEG-based diagnostic solutions.
Upturn SWOT Analysis
Strengths
- Proprietary EEG analysis algorithms
- Potential for personalized treatment strategies
- Focus on objective, quantitative brain health insights
Weaknesses
- Limited market share due to being a smaller company
- Dependence on regulatory approvals
- Requires substantial capital investment
Opportunities
- Growing demand for objective measures in cognitive and mental health
- Expansion into new clinical applications
- Partnerships with pharmaceutical companies
Threats
- Competition from established players in the EEG diagnostics market
- Technological advancements that could render its technology obsolete
- Changes in regulatory environment
Competitors and Market Share
Key Competitors
- N/A
Competitive Landscape
Without publicly available information on market share and financials it is difficult to evaluate Fireflyu2019s competitive advantages relative to competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Not Available
Future Projections: Not Available
Recent Initiatives: Recent initiatives include platform updates and expanding its clinical applications.
Summary
Firefly Neuroscience aims to provide objective brain health insights for clinical decision-making using EEG analysis. It faces the challenges of market penetration against established competitors and the need for regulatory approvals. The company's strengths lie in its proprietary algorithms and potential for personalized treatments, but limited market share and financial transparency pose hurdles. Future opportunities involve expanding clinical applications and partnering with pharmaceutical companies.
Similar Companies
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Press Releases
Disclaimers:
The information provided is based on publicly available sources and is subject to change. Market share data is not readily available and may be estimated. This analysis is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Firefly Neuroscience, Inc.
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2011-02-23 | CEO & Director Mr. Greg Lipschitz | ||
Sector Technology | Industry Software - Application | Full time employees 7 | Website https://fireflyneuro.com |
Full time employees 7 | Website https://fireflyneuro.com | ||
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.